Sorafenib increases survival rate of patients with advanced hepatocellular carcinoma
(HCC). The mechanism underlying this effect is not completely understood. In this work we …

The multi-kinase inhibitor Sorafenib increases the survival of patients with advanced
hepatocellular carcinoma (HCC). Current data suggest that Sorafenib inhibits cellular …

Although sorafenib was approved as antiangiogenic agent in case of hepatocellular
carcinoma (HCC), the pathways mediating its antitumorigenic effects were not fully …

The small molecule multi-kinase inhibitor sorafenib has become the standard systemic
treatment for patients with advanced hepatocellular carcinoma (HCC) and renal cell …

BACKGROUND & AIMS: Previously we reported that Akt inactivation determines the
sensitivity of hepatocellular carcinoma (HCC) cells to bortezomib. Here we report that …

Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer and the
fourth most frequent cause of cancer-related death worldwide. Sorafenib is the first line …

The multikinase inhibitor sorafenib is the only effective drug in advanced cases of
hepatocellular carcinoma (HCC). However, response differs among patients and …

Sorafenib (Nexavar, BAY43-9006), a bi-arylurea, is a newly established anti-cancer drug
and its functional attribute of cytotoxicity is based on the multi-kinase inhibitory action. Here …

The purpose of this study was to investigate the effect of bufalin on the anti-proliferative
activity of sorafenib in the human hepatocellular carcinoma (HCC) cell lines PLC/PRF/5 and …

Background Advanced hepatocellular carcinoma (HCC) responds poorly to conventional
systemic therapies. Therefore, new effective therapy strategies are urgently needed …